Serum galectin-3 and fibroblast growth factor-23 levels in relation with type 2 diabetes and cardiovascular risk.

IF 2 4区医学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY

Journal of Medical Biochemistry Pub Date : 2025-01-24 DOI:10.5937/jomb0-50471

Aleksandra Klisic, Sanja Gluscevic, Paschalis Karakasis, Jelena Kotur-Stevuljevic, Ana Ninic

{"title":"Serum galectin-3 and fibroblast growth factor-23 levels in relation with type 2 diabetes and cardiovascular risk.","authors":"Aleksandra Klisic, Sanja Gluscevic, Paschalis Karakasis, Jelena Kotur-Stevuljevic, Ana Ninic","doi":"10.5937/jomb0-50471","DOIUrl":null,"url":null,"abstract":"Background: The clinical utility of galectin-3 and fibroblast growth factor 23 (FGF-23) needs to be further explored since previous studies show divergent results in relation to type 2 diabetes (T2D) and cardiovascular risk. Hence, the aim of this research was to explore galectin-3 and FGF-23 in relation to T2D, as well as to examine the potential association of these biomarkers with atherosclerotic cardiovascular disease (ASCVD) risk score in Montenegrin adults.Methods: A total of 35 T2D patients and 36 controls were consecutively enrolled. Serum galectin-3 and FGF-23 were determined by ELISA. The ASCVD risk score was calculated.Results: Higher serum galectin-3 levels were shown in T2D patients (p=0.016) in comparison with the control group. The increase in galectin-3 levels for 1 ng/mL showed an 8.5% higher probability of T2D occurrence (OR=1.085, p=0.015). FGF-23 levels did not differ between the control and the T2D group. Serum galectin-3 correlated with FGF23 (r=0.390, p=0.001). Both galectin-3 (r=0.306, p=0.010) and FGF-23 (r=0.332, p=0.005) correlated with ASCVD risk score in bivariate Spearman's correlation analysis, but these correlations were not retained in binary logistic regression analysis.Conclusions: Serum galectin-3 levels but not FGF-23 are higher in T2D patients. Serum galectin-3 correlated with FGF-23. Although both biomarkers were correlated with the ASCVD risk score, further statistical analysis did not confirm their independent associations with cardiovascular risk. Studies with a large sample size are needed to further explore this issue.","PeriodicalId":16175,"journal":{"name":"Journal of Medical Biochemistry","volume":"44 1","pages":"85-92"},"PeriodicalIF":2.0000,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11846640/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical Biochemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5937/jomb0-50471","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The clinical utility of galectin-3 and fibroblast growth factor 23 (FGF-23) needs to be further explored since previous studies show divergent results in relation to type 2 diabetes (T2D) and cardiovascular risk. Hence, the aim of this research was to explore galectin-3 and FGF-23 in relation to T2D, as well as to examine the potential association of these biomarkers with atherosclerotic cardiovascular disease (ASCVD) risk score in Montenegrin adults.

Methods: A total of 35 T2D patients and 36 controls were consecutively enrolled. Serum galectin-3 and FGF-23 were determined by ELISA. The ASCVD risk score was calculated.

Results: Higher serum galectin-3 levels were shown in T2D patients (p=0.016) in comparison with the control group. The increase in galectin-3 levels for 1 ng/mL showed an 8.5% higher probability of T2D occurrence (OR=1.085, p=0.015). FGF-23 levels did not differ between the control and the T2D group. Serum galectin-3 correlated with FGF23 (r=0.390, p=0.001). Both galectin-3 (r=0.306, p=0.010) and FGF-23 (r=0.332, p=0.005) correlated with ASCVD risk score in bivariate Spearman's correlation analysis, but these correlations were not retained in binary logistic regression analysis.

Conclusions: Serum galectin-3 levels but not FGF-23 are higher in T2D patients. Serum galectin-3 correlated with FGF-23. Although both biomarkers were correlated with the ASCVD risk score, further statistical analysis did not confirm their independent associations with cardiovascular risk. Studies with a large sample size are needed to further explore this issue.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Medical Biochemistry BIOCHEMISTRY & MOLECULAR BIOLOGY-

CiteScore

3.00

自引率

12.00%

发文量

审稿时长

>12 weeks

期刊介绍： The JOURNAL OF MEDICAL BIOCHEMISTRY (J MED BIOCHEM) is the official journal of the Society of Medical Biochemists of Serbia with international peer-review. Papers are independently reviewed by at least two reviewers selected by the Editors as Blind Peer Reviews. The Journal of Medical Biochemistry is published quarterly. The Journal publishes original scientific and specialized articles on all aspects of clinical and medical biochemistry, molecular medicine, clinical hematology and coagulation, clinical immunology and autoimmunity, clinical microbiology, virology, clinical genomics and molecular biology, genetic epidemiology, drug measurement, evaluation of diagnostic markers, new reagents and laboratory equipment, reference materials and methods, reference values, laboratory organization, automation, quality control, clinical metrology, all related scientific disciplines where chemistry, biochemistry, molecular biology and immunochemistry deal with the study of normal and pathologic processes in human beings.